Equity strategies

Carmignac Portfolio Grandchildren

Luxembourg SICAV sub-fundGlobal marketSRI Fund Article 9
Share Class

LU2427320739

An intergenerational Fund focused on quality, sustainable companies
  • A Fund focused on selecting high-quality companies around the world, with sound financials and sustainable profitability.
  • An investment process based on rigorous fundamental analysis, quantitative screening, and a socially responsible investment approach.
Asset Allocation
Equities95.1 %
Other4.9 %
Data as of:  30 Sep 2024.
Risk Indicator
4/7
Recommended Minimum Investment Horizon
5 years
Cumulative Performance since launch
+ 11.1 %
0.0 %
0.0 %
0.0 %
+ 23.8 %
From 05/11/2024
To 05/11/2024
Calendar Year Performance 2023
-
-
-
-
-
-
-
-
- 19.5 %
+ 20.7 %
Net Asset Value
108.24 £
Asset Under Management
533 M €
Market
Global market
SFDR - Fund Classification

Article

9
Data as of:  5 Nov 2024.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.

Carmignac Portfolio Grandchildren fund performance

Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.

Our monthly comments

Data as of:  30 Sep 2024.
Fund management team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
[Management Team] [Author] Ejikeme Obe

Obe Ejikeme

Fund Manager, Analyst

Market environment

  • Major indices reached all-time highs during the month, driven by monetary easing from central banks.

  • Chinese equities surged towards the end of the period as Beijing's stimulus measures boosted optimism about the recovery of the world's second-largest economy. These measures aim to counter monetary contraction, address the collapse in the property market, and revive the struggling stock market.

  • The Federal Reserve initiated its easing cycle with an aggressive 50 basis point cut in its key rate, while the European Central Bank continued to reduce its key rates by 25 basis points.

  • Economic indicators in the United States remain robust, with rising retail sales and industrial production, a mixed but solid employment market, and falling inflation. In contrast, economic activity in the eurozone has been more lackluster.

Performance commentary

  • The Fund underperformed its reference inidcator over the month.- Our equities portfolio was negatively impacted by the poor monthly performance of Novo Nordisk. The stock declined following the presentation of mixed phase 2a clinical data on its new experimental treatment for obesity, Monlunabant.- The Fund was also affected by our other long-term holdings in the healthcare sector, including Vertex, Genmab, and Demant.- Our underexposure to consumer discretionary stocks, in favor of consumer staples, prevented us from capitalizing on the sector's rise due to announcements from the Chinese government.- Conversely, our high-quality technology stocks performed well, as demonstrated by the strong performance of SAP, Microsoft, and Oracle, which reported good results, particularly in terms of demand for their cloud infrastructure services.

Outlook strategy

  • In line with our strategy, we remain cautious and favor defensive-quality companies in the context of a global economic slowdown. However, we have made a few adjustments to the portfolio.- Firstly, we have slightly increased our exposure to technology stocks, which have suffered in recent months, particularly in the semiconductor sector. - These increases were financed by profit-taking in companies that have performed well over the past 12 months, such as P&G, Colgate, and S&P Global.- Finally, we took advantage of the rebound in consumer discretionary stocks following the Chinese announcements to sell our remaining stake in Estée Lauder.

Performance Overview

Data as of:  31 Oct 2024.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Source: Carmignac at 05/11/2024

Carmignac Portfolio Grandchildren Portfolio overview

Below is an overview of the composition of the portfolio.

Geographical Breakdown

Data as of:  30 Sep 2024.
North America67.1 %
Europe32.9 %
Total % Equities100.0 %
North America67.1 %
usUSA
67.1 %

Key figures

Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.

Exposure Data

Data as of:  30 Sep 2024.
Equity Investment Weight95.1 %
Net Equity Exposure95.1 %
Number of Equity Issuers42
Active Share81.8 %

The strategy in a nutshell

Discover the Fund’s main features and benefits through the words of the Fund Managers.
Fund Management Team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
[Management Team] [Author] Ejikeme Obe

Obe Ejikeme

Fund Manager, Analyst
Carmignac Portfolio Grandchildren is an intergenerational Fund that focuses on high-quality companies to help investors build capital not only for themselves, but also for future generations.
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
View Fund's characteristics
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
​The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performance is shown net of fees (excluding any subscription fees payable to the distributor). Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.

Related articles

Corporate22 October 2024English

Changes to the prospectus of Carmignac Portfolio

3 minute(s) read
Find out more
Sustainable investing10 July 2024English

Carmignac’s Article 9 funds: a sustainable investment?

3 minute(s) read
Find out more
Global equities8 December 2023English

Building the world of tomorrow with Carmignac Portfolio Grandchildren

5 minute(s) read
Find out more